| Amarantus BioSciences, Inc. (OTCBB:AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein that mitigates an underlying cause of cell death known as apoptosis and is currently in development for the treatment of Parkinson's disease, today announced that Mr. Gerald Commissiong has been appointed to President & Chief Executive Officer and will remain a member of the Board of Directors where he has served since 2008. Mr. Commissiong will repla...continued AMBS |
Friday, October 28, 2011
Amarantus BioSciences Appoints Gerald Commissiong President & CEO
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment